tirzepatide and iih Efficacy of Dual GIP/GLP‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched Study - Azzam - 2025 - Endocrinology, Diabetes & Metabolism Have You Used Ozempic, Wegovy

Case reports in youths have noted exacerbation or new onset of tics and repetitive compulsive behaviors [41,42]

Key Takeaway: Tirzepatide has been shown to reduce systolic blood pressure by an average of 7 to 10 mmHg in clinical trials, offering benefits that may rival some traditional blood pressure medications

(PubMed) Gao S, Ding LH, Wang JW, Li CB, Wang ZY

plays a pivotal role in ensuring that patients receive reliable and effective medications

While the inherent pharmacokinetic properties of each GLP-1 receptor agonist largely determine elimination time, several patient-specific factors can influence how quickly or slowly these medications clear from the body